Research
Malaria antibody protects infants but lowers immune response to R21 vaccine, trial finds
The Brief
- A single intramuscular dose of the experimental malaria monoclonal antibody L9LS safely gave infants strong protection during Mali's six-month malaria season.
- The antibody may interfere with the immune response to the R21 malaria vaccine.
- This potential interference puts plans to pursue development of L9LS in question.
Why it matters
Monoclonal antibodies could offer a complementary tool against malaria in infants, but if they blunt vaccine responses, combined immunization strategies would need to be reconsidered.
Who’s affected
- malaria researchers and clinicians
- public health planners in malaria-endemic regions
A single intramuscular dose of an experimental malaria monoclonal antibody safely provided infants with strong protection during Mali's six-month malaria season. However, potential interference with the R21 malaria vaccine is putting plans to pursue development of L9LS for this…